Overview

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with mNSCLC treated in the 2nd or 3rd line setting.

Phase:

Phase 2

Details

Lead Sponsor:

G1 Therapeutics, Inc.

Treatments:

Docetaxel